

# Osteoarthritis and Cartilage



## Metabolic stress-induced joint inflammation and osteoarthritis



A. Courties †, O. Gualillo ‡, F. Berenbaum †\*, J. Sellam †

† Rheumatology Department, Saint-Antoine Hospital, Inserm UMR S\_938, UPMC Univ Paris 06, Assistance Publique – Hôpitaux de Paris (AP-HP), DHU i2B, Paris, France

‡ SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sainitaria de Santiago), the NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Santiago de Compostela, Spain

### ARTICLE INFO

#### Article history:

Received 8 January 2015  
Received in revised form  
20 April 2015  
Accepted 20 May 2015

#### Keywords:

Osteoarthritis  
Inflammation  
Metabolic syndrome  
Obesity  
Adipokines  
Oxidative stress

### SUMMARY

Osteoarthritis (OA) is a heterogeneous disorder with several risk factors. Among them, obesity has a major impact on both loading and non-loading joints. Mechanical overload and activity of systemic inflammatory mediators derived from adipose tissue (adipokines, free fatty acids (FFA), reactive oxygen species (ROS)) provide clues to the increased incidence and prevalence of OA in obesity. Recently, research found greater OA prevalence and incidence in obese patients with cardiometabolic disturbances than “healthy” obese patients, which led to the description of a new OA phenotype – metabolic syndrome (MetS)-associated OA. Indeed, individual metabolic factors (diabetes, dyslipidemia, and hypertension) may increase the risk of obesity-induced OA. This review discusses hypotheses based on pathways specific to a metabolic factor in MetS-associated OA, such as the role of advanced glycation end products (AGEs) and glucose toxicity. A better understanding of these phenotypes based on risk factors will be critical for designing trials of this specific subset of OA.

© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

### Introduction

Osteoarthritis (OA) is a chronic joint disease leading to cartilage degradation that involves synovial inflammation, subchondral bone remodeling and the formation of osteophytes<sup>1,2</sup>. Cartilage degradation results from ruptured joint homeostasis that favors catabolic processes activated by pro-inflammatory mediators such as cytokines, lipid mediators and reactive oxygen species (ROS), which are produced as well by chondrocytes, synoviocytes and osteoblasts<sup>3,4</sup>. These products are responsible for altering anabolism and release of proteolytic enzymes degrading extracellular matrix.

We can differentiate OA phenotypes according to risk factors such as aging, genetics, trauma, obesity and metabolic disorders<sup>4</sup>. Despite eventual joint failure, the pathogenic pathways leading to this end may differ among phenotypes. This review gives epidemiological and mechanistic insights into metabolic syndrome (MetS)-associated OA, in which metabolic disorders and low-grade inflammation have a central role<sup>5</sup>. We discuss especially the relevant mechanisms involved in inflammation related

to excess fat mass and metabolic disturbances and their implication in OA and in pain-related OA. The references for this review were limited to papers published in English in PubMed and were selected according to their relevance to the topic and after critical discussion.

### Epidemiology of MetS-associated OA

As endemic diseases of the twenty-first century, obesity and overweight are among the most important risk factors of OA<sup>6,7</sup>. Such an association cannot be solely explained by excessive mechanical stress because the rate of hand OA (HOA) is two-fold higher in obese patients than lean subjects<sup>8</sup>. Thus, excess fat mass has a systemic harmful role in joints.

From an epidemiological perspective, assessing obesity in studies remains a crucial issue<sup>9</sup>. The most accurate anthropometric marker of fat mass distribution is the waist/hip ratio (WHR)<sup>10</sup>. Besides weight, android (or visceral) obesity is highly linked to metabolic comorbidities and cardiovascular (CV) events as compared with gynoid obesity<sup>11–14</sup>. As well, the association of fat mass distribution (i.e., WHR or impedance analysis) and OA has been studied. Hand, knee and hip OA incidence and severity are associated with fat mass distribution and especially visceral and central adiposity<sup>15,16</sup>. However, such associations are fewer than

\* Address correspondence and reprint requests to: F. Berenbaum, Hôpital Saint-Antoine, AP-HP, Service de Rhumatologie, 184 Rue du Faubourg Saint-Antoine, 75012 Paris, France. Tel: 33-149-28-25-20; Fax: 33-149-28-25-13.

E-mail address: francis.berenbaum@sat.aphp.fr (F. Berenbaum).

those with body mass index (BMI) for weight-bearing joints (i.e., knee and hip OA)<sup>7</sup>.

Considering the harmful systemic impact of excess fat mass, the role of systemic metabolic disorders in OA has become of interest. MetS is an accumulation of metabolic disorders leading to an increased risk of stroke, type 2 diabetes mellitus and CV diseases<sup>17,18</sup>. Despite several definitions, all disorders include abdominal obesity, increased blood pressure, impaired glucose tolerance and lipid abnormalities such as high triglycerides level and low high-density lipoprotein cholesterol level<sup>19–21</sup>. MetS and OA share a strong association with obesity and age, and adjustment for these parameters is crucial to correctly analyze the associations between them. The risk of onset, pain and progression of knee OA as well as rate of knee and hip arthroplasty increase with the accumulation of MetS components<sup>22–24</sup>. The cumulative impact of metabolic disturbances in obese patients is also observed in HOA<sup>25</sup>. Whereas an association between MetS and hand OA is quite well demonstrated in the literature, this is not the case for knee OA<sup>26</sup>. As illustrated by Visser *et al.*, this discrepancy could be due to a critical role of overload on weight-bearing joints which could mask any underlying roles of metabolic disorders<sup>27</sup>. Eventually, being obese with other components of MetS confers an increased risk of OA as compared with being only obese. On the other side, OA is associated with increased prevalence of MetS, especially in the youngest population, and some authors have suggested that a diagnosis of OA before 65 years should lead to a systematic screening for MetS<sup>28</sup>.

Beyond the association of OA with MetS, OA could be also linked to each metabolic disorder separately. The most relevant evidence is probably for type 2 diabetes or hyperglycemia<sup>22,29,30</sup>. Type 2 diabetic patients have a two-fold higher need for hip and knee arthroplasty (i.e., suggesting a more severe form of OA) after adjustment for confounding factors and display more frequently knee synovitis on ultrasonography than non-diabetic OA patients<sup>30</sup>. Furthermore, in the Rotterdam study, for patients 55–62 years old, type 2 diabetes increased the risk of HOA<sup>25</sup>. In addition, diabetes mellitus is associated with increased pain in erosive HOA<sup>31</sup>. These data on knee and HOA were confirmed in other studies and in a meta-analysis that reported an overall 43% increased risk of OA in type 2 diabetic patients<sup>32,33</sup>.

All studies of OA reported high hypertension prevalence, but the independent association remains rare after adjustment for confounding factors such as age or BMI<sup>23,26</sup>. However, two recent studies demonstrated an independent but weak association regardless of BMI<sup>22,24</sup>. To date, hypertension should be considered an aggravating factor for OA in subjects with obesity or other metabolic disturbances<sup>25</sup>.

Finally, an association between dyslipidemia and OA has been reported. Hypercholesterolemia has been associated with HOA and generalized OA regardless of age, gender and BMI<sup>34,35</sup>.

### OA, cardiovascular risk and related mortality

The main concern about MetS-associated OA is its potential association with atherosclerosis and death due to CV events. Radiographic OA was found independently associated with atherosclerosis of carotid, femoral and coronary vessels<sup>36–39</sup>. Furthermore, atherosclerosis severity increases when HOA is associated with knee or hip OA<sup>40</sup>. As well, OA has been associated with higher age- and sex-standardized CV mortality incidence ratio than expected in the general population<sup>41</sup>. However, data remains controversial, and no increase of mortality in the OA population was also reported<sup>42</sup>. Some authors have suggested that OA-related disability could explain the higher CV mortality raising the question of reciprocity between OA and cardiometabolic diseases. Thus, OA induced disability which in turn promotes obesity and its

cardiometabolic comorbidities<sup>43</sup>. However, beyond this induced disability, OA may be responsible for a low-grade inflammation state *via* a joint release of inflammatory mediators into the blood stream that could in turn aggravate cardiometabolic diseases such as atherosclerosis<sup>44</sup>. Interestingly, an independent association has recently been shown between increased popliteal artery wall thickness and subsequent knee cartilage degradation seen on MRI in asymptomatic and non-disabled subjects<sup>45</sup>.

### Inflammation in MetS and its involvement in OA

During the past decade, obesity and metabolic disorders have been found related to systemic low-grade chronic inflammation characterized by abnormal cytokine production, increased levels of acute-phase reactants and activation of a network of inflammatory signaling pathways<sup>5,46</sup>. Fat mass is the cornerstone of this inflammation, but diabetes, dyslipidemia and hypertension have specific involvement in metabolic inflammation, which could be implicated in OA pathogenesis. Here, we focus on the harmful biological mechanisms of fat mass and metabolic disorders in the joint, with special emphasis on inflammatory factors (Fig. 1) and possible future developments in this topic.


#### *The key mechanisms of metabolic stress*

##### *Adipokines*

Several novel biochemical players were identified in the last 2 decades after the discovery of leptin, in 1994, the forerunner of a large superfamily of proteins collectively called adipokines<sup>47</sup>. Most of these proteins, secreted systematically by white adipose tissue but also by all cells of the joint (including chondrocytes, synovial cells, adipocytes of periarticular fat tissue and bone cells) participate in the degrading process of OA in several ways: supporting chronic inflammation, increasing oxidative stress and participating in other pathologic complications associated with OA (i.e., CV and metabolic diseases)<sup>48,49</sup>. Likewise, lots of studies have shown adipokines disturbances (i.e., serum level, synovial fluid level or tissular expression) as a common characteristic of chronic inflammation in OA<sup>50</sup>. Although we will not discuss in detail the role of individual adipokines in OA (widely discussed elsewhere<sup>51,52</sup>), we summarize the most salient aspects that link adipokines to OA.

With the exception of adiponectin, circulating levels of adipokines (e.g., leptin, visfatin and resistin) are elevated in patients with OA and are gender-dependent, even after adjustment for BMI, so these molecules might be responsible for the higher prevalence of OA in women than men. Most of the adipokines identified to date have pro-inflammatory activities, by inducing the synthesis of other related pro-inflammatory adipokines and cytokines, increasing the synthesis of aggrecanases and metalloproteases, of ROS levels as well as nitrogen radicals such nitric oxide (NO), and prostaglandin levels.

The most studied adipokine is undoubtedly the leptin. Mainly produced by white adipocytes (but also by joint cells), its serum level correlated to the weight and fat mass. It plays an essential role in homeostasis (thermogenesis, food intake, lipolysis, and gluconeogenesis). Its synovial expression correlates also with BMI<sup>53</sup> and with OA prevalence and severity<sup>54</sup>. *In vitro*, leptin induces the production of cytokines by synoviocytes (IL-6 and IL-8)<sup>55,56</sup>, chondrocytes (IL-1 $\beta$ , MMP-9 and MMP-13)<sup>54</sup> and cartilage explants (IL-6, IL-8, PGE2)<sup>57</sup>. Leptin levels in chondrocytes could be increased by epigenetic regulations such as DNA methylation of leptin which is decreased in OA chondrocytes. Indeed, DNA methylation of leptin promoter gene leads to an upregulation of leptin expression which in turns increased its catabolic activity through MMP-13 production<sup>58</sup>. However, some anabolic aspects of leptin have been



**Fig. 1.** Major metabolic stress inducing inflammation in chondrocytes. We hypothesize that, in the metabolic OA phenotype, several pathways and metabolic stress factors are involved: (1) obesity activates chondrocytes through mechanical signals but also through adipokines (i.e., leptin and visfatin) (2) insulin resistance limits pro-anabolic effects of insulin and enhances FFA production which is also responsible for chondrocyte activation via TLR-4 (3) at end-stage, diabetes mellitus induces ROS and cytokine production triggered by hyperglycemia and AGE. All these stresses induce ROS and pro-inflammatory cytokines which both play a major role in joint inflammation, proteolytic enzymes production and subsequent cartilage degradation. RAGE: receptor for AGE; Ob-R: receptor for leptin.

reported. For instance, leptin can induce insulin growth factor 1 (IGF-1) and transforming growth factor-beta in cartilage, perhaps protecting cartilage against osteoarthritic degeneration or participating in osteophyte development<sup>53</sup>.

As well, visfatin could increase the rate of IL-6 and MCP-1 by chondrocytes<sup>59</sup> and decrease the pro-anabolic effect of IGF-1<sup>60</sup>. Also known as nicotinamide phosphoribosyltransferase (NAMPT), visfatin has been shown to modulate other enzyme expression such as sirtuin 1 (Sirt1), an histone deacetylase, which is an epigenetic regulator<sup>61</sup>. Sirt1 has been involved in cartilage biology and OA pathogenesis but also in type II diabetes and other aging-related diseases and could be another link between OA and MetS<sup>52,63</sup>.

Finally, even adiponectin, in contrast to its protective role in cardiovascular diseases and obesity, shows pro-inflammatory activities like the production of NO synthase 2, IL-6 and MCP-1, triggering matrix degradation by inducing MMP-3 and MMP-9 expression in chondrocytes<sup>64,65</sup>.

Eventually, despite the possible protective role of leptin, there is a general consensus that adipokines exert a catabolic and pro-inflammatory effect on cartilage. Only 20 years after the discovery of leptin, the first identified, adipokines are considered to play multiple important biological roles, and the increasing research effort in this area is gradually revealing the intricate adipokine-mediated interplay among white adipose tissue, metabolic disorders and inflammatory degenerative joint disorders such as OA.

Although many issues remain unclear, several possible avenues that these works have opened can be sketched. In particular, from a metabolic point of view, one should remember that the primary causes of obesity-related hyperproduction of detrimental adipokines are generally nutritional and lifestyle factors such as over-eating and physical inactivity and that front-line treatment essentially involves the correction of these factors. Knowledge of the actions of the newer adipokines is still too incomplete to generate well-supported therapeutic hypotheses. However, by the

rate at which their roles are being clarified, they will soon be central to pharmacotherapeutic approaches to obesity-induced inflammatory diseases. For example, in light of the pro-inflammatory role of visfatin on joint cells, this adipokine has been therapeutically blocked in a murine model of OA with efficacy<sup>59,66</sup>.

#### Oxidative stress

Oxidative stress is a cellular response in which the synthesis of intracellular ROS goes beyond the ability of the cell to neutralize the molecules, thus leading to final cellular damage and in some cases cell death<sup>67</sup>. Oxidative stress has been involved in several pathophysiological conditions including aging, cancer, and CV diseases as well as metabolic diseases and obesity<sup>68,69</sup>. ROS and or nitrogen radicals (nitric oxide [NO]) are important players in the inflammatory process occurring in OA<sup>70,71</sup>. Actually, almost all the OA joint cells, including chondrocytes, synovial fibroblasts and adipocytes, can produce large amounts of ROS and NO in response to biomechanical or biochemical stimuli. In this regard, most of biomechanical-induced ROS are likely produced by mitochondria, and recent evidence suggests that mitochondrial dysfunction may contribute to the development of OA<sup>72</sup>. Indeed, *in vitro* data showed that in certain biomechanical conditions, mitochondria can release large amounts of ROS in cartilage, thus leading to cell death (REF A DEMANDER préciser les certain biomechanical conditions). ROS are thought to participate in several processes of the inflammatory response in OA in particular by triggering specific intracellular pathways such those elicited by nuclear factor kappa B (NF- $\kappa$ B), hypoxia-inducible factor 1 alpha (HIF-1 $\alpha$ ) or activating protein 1 (AP-1)<sup>73</sup>. Although high levels of ROS are clearly detrimental to joint cell populations, some evidence suggests that cellular energy supply in chondrocytes relies on the availability of mitochondrial ROS to produce ATP, which suggests that physiological or sublethal levels of these molecules may have implications in cartilage biology. Indeed, *in vivo* studies suggest that physical exercise (at both extremes:

high-intensity or sedentary activity) is related to high levels of ROS and therefore increased risk of cartilage lesions. In contrast, moderate physical exercise, with low ROS levels, may favor healthy cartilage. Thus, a low adequate level of ROS might have a cartilage-protective role by eliciting increased matrix synthesis and/or activating specific protective pathways that finally lead to inflammation suppression or control, with imbalanced ROS synthesis and accumulation leading to degenerative effects<sup>74</sup>. Of note, several adipokines, but also high glucose level, may be considered the link between oxidative stress and the mechanisms of obesity-associated metabolic syndrome<sup>75</sup>. Actually, leptin, adiponectin and lipocalin-2 can induce accumulation of NO and activation of NO synthase type 2 in chondrocytes and other joint cells<sup>76</sup>.

#### Free fatty acids (FFA) and the high-fat diet

The increased dietary fat content that characterizes the diet of industrialized countries in the last 30–40 years clearly contributes to both obesity and the metabolic dysfunction associated with type 2 diabetes. Nutritional aspects, particularly fat intake, are involved in the development of OA-associated obesity. Dietary polyunsaturated fatty acids (PUFAs) of both the n-3 and the n-6 series are essential for human health but may have opposite effects on inflammatory responses: n-6 PUFAs likely give rise to inflammatory eicosanoids, whereas n-3 PUFAs are generally anti-inflammatory. High levels of fatty acids are found in joint tissues in OA and are associated with severe tissular lesions<sup>77</sup>. *In vitro*, palmitate, a saturated FFA induced pro-inflammatory cytokines production by chondrocytes and synoviocytes via the Toll-like Receptor-4 (TLR-4) and has pro-apoptotic effects<sup>78</sup>. In animal models, a high-fat diet accelerated the progression of OA; n-3 PUFAs limited disease severity, thus corroborating their anti-inflammatory and anti-degradative effect on chondrocytes, and n-6 PUFAs had no detrimental effect<sup>79–81</sup>. A diet containing significant levels of eicosapentaenoic acids and docosahexaenoic acids may reduce joint stiffness and tenderness in arthritic patients<sup>82,83</sup>.

#### PPAR gamma and autophagy

Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factor of the nuclear receptor superfamily and play a major role in homeostasis. Among them, PPAR gamma (PPAR $\gamma$ ) is the pivotal transcription factor leading to adipogenesis and increasing sensitivity to insulin explaining why PPAR $\gamma$  agonists such as glitazones take place in the therapeutic armamentarium against diabetes mellitus<sup>84</sup>. Interestingly, the role of PPAR $\gamma$  has been studied in OA too. Its expression seems to be decreases in the OA joint tissues<sup>85</sup>. *In vitro*, PPAR $\gamma$  agonists are protective by decreasing the production of pro-inflammatory and catabolic mediators by chondrocytes and synoviocytes<sup>86–88</sup>. As well, PPAR $\gamma$  inducible-cartilage knockout mice develop accelerated OA with increased cartilage degradation and decreased autophagy responsible for an impairment of cartilage homeostasis<sup>89</sup>. Interestingly, loss of autophagy is also observed in obesity and other metabolic diseases<sup>90</sup>. All these data suggest that PPAR $\gamma$  plays a crucial role in maintaining homeostasis of the joint and could be one of the mechanisms linking OA to obesity and other metabolic comorbidities.

#### Advanced glycation end products (AGEs)

AGEs result from the non-enzymatic and posttranslational addition of reduced sugars on proteins or apolipoproteins. Because of their multiple ways of formation and their different half-lives, they constitute a heterogeneous group of chemical species. The most famous AGE is glycated hemoglobin A (HbA1c), used in clinical practice to monitor diabetes. Pentosidine and N-epsilon-carboxymethyllysine, because of their antigenic properties, have also been studied<sup>91</sup>. The molecules accumulate in tissues during aging,

but their production is also highly related to glycemia<sup>92</sup>. These AGEs are involved in diabetes onset and complications<sup>93</sup>. Some steps of AGE formation depend on PUFA peroxidation and oxidative stress, so they are also associated with obesity<sup>94,95</sup>.

First, accumulation of extracellular AGEs exerts a harmful role by modifying the mechanical properties of the tissue. Indeed, their accumulation in the collagen network increases the stiffness and fragility of cartilage and bone<sup>96,97</sup>. AGEs accumulate in retina, kidney, vessels or skin in diabetic patients, but also in diabetic OA joint tissues<sup>98–101</sup>. OA diabetic patients show a higher rate of pentosidine in the subchondral bone than do non-diabetic OA patients<sup>102</sup>. They also act by triggering a receptor-dependent pathway, involving the receptor of AGE (RAGE). *In vitro* studies demonstrate that binding of AGEs on RAGE activates NF- $\kappa$ B and p38 mitogen-activated protein kinase signaling pathways leading to the production of pro-inflammatory cytokines, proteolytic enzymes and ROS in chondrocytes and synoviocytes<sup>103–108</sup>. AGEs also induce chondrocyte apoptosis<sup>109</sup> and participate in cartilage aging as their accumulation is also age-related<sup>110</sup>. A potential limitation of these receptor-related studies could be the use of a non-specific mixture of AGEs like glycated albumin which may not be relevant to the glycated proteins expected in cartilage such as type II collagen.

#### Hyperglycemia and insulin resistance

Diabetes mellitus-related OA belongs to the MetS-associated OA phenotype. Hyperglycemia and insulin resistance may explain the relationship between diabetes and OA. In the streptozotocin-induced diabetic rat model, characterized by a strong hyperglycemia due to chemical destruction of pancreatic  $\beta$ -cells, type 2 collagen and proteoglycan content was spontaneously decreased in cartilage, which suggests a noxious role of hyperglycemia in cartilage<sup>111</sup>. Glucose incorporation in chondrocytes is mediated by glucose transporters (GLUTs). The main GLUTs expressed by chondrocytes are GLUT-1, -3 and -9<sup>112</sup>. GLUT-3 expression is constitutive, whereas GLUT-1 and -9 are inducible by cytokines (e.g., interleukin 1 $\beta$  [IL-1 $\beta$ ]) and glucose concentration, thereby allowing chondrocytes to adapt glucose incorporation depending on the extracellular concentration<sup>113</sup>. *In vitro*, human OA chondrocytes lose this ability, which leads to increased incorporation in a high-glucose environment<sup>75</sup>. Once integrated in the cell, glucose is metabolized via different pathways such as the glycolysis and polyol pathways but also the protein kinase C and pentose/hexosamine pathways, all known to result in ROS production in other cell types and could explain why high glucose concentration increases ROS formation in chondrocytes<sup>75,114</sup>.

Insulin resistance may also be implicated. Insulin levels are higher in overweight patients with OA than without OA<sup>115</sup>. Chondrocytes and synoviocytes are insulin-sensitive cells because they express the insulin receptor. Recently, synoviocytes in diabetic patients were found to be insulin-resistant<sup>116</sup>. Furthermore, with high glucose concentrations, chondrocytes lose their responsiveness to IGF-1. Insulin is an anabolic hormone inducing matrix component synthesis, so insulin resistance may limit anabolic processes of cartilage<sup>117</sup>.

#### Vascular involvement

Oxygenation and nutrients arrive at avascular cartilage from synovial fluid and subchondral bone. Since OA is associated with hypertension and atherosclerosis, compromised vascularization of the subchondral bone may be responsible for OA exacerbation<sup>118,119</sup>. Two phenomena can induce impaired blood flow: reduced arterial inflow (such as ischemia) and obstruction of venous outflow. Early bone-marrow lesions observed on MRI in OA could correspond to ischemic lesions but, to date, no histological proof is available. In a female rat model, inducing thrombosis of subchondral bone in a temporo-mandibular joint led to OA, which

suggested the role of vascularization in joint homeostasis<sup>120</sup>. Furthermore, angiogenesis, to counteract ischemia, is involved in OA pathogenesis. Indeed, abnormal vascular channels occur in calcified cartilage during OA, which enhances the permeability to inflammatory mediators<sup>121</sup>. However, a specific relation with hypertension or atherosclerosis needs further investigation.

#### Other paths?

##### Gut microbiota

Another systemic connection between MetS, obesity and OA could be gut microbiota<sup>122</sup>. The absorption of endotoxins across the intestinal tract seems highly implicated in systemic low-grade inflammation related to obesity and metabolic disorders<sup>123</sup>. Modification of dietary intake, such as a high-fat diet, affects gut microbiota, thereby increasing the inflammatory state, regardless of weight loss<sup>124</sup>. For example, the relation between a high-fat diet and OA previously described suggests the effect of microbiota on OA; indeed, a high-fat diet markedly affects gut microbiota by modifying the bacterial composition and functional response<sup>125</sup>. Furthermore, bacterial lipopolysaccharide strongly induces pro-inflammatory chondrocytes via TLR-4, for a potential mechanism to explain how endotoxaemia may favor OA<sup>126</sup>. Data are limited in this field, and the role of microbiota in OA onset and inflammation-related OA in the MetS-associated OA phenotype need further investigation.

##### Genetics

Lifestyle and environment seem key factors in the onset and progression of metabolic diseases, but obesity and type 2 diabetes are also subject to genetic susceptibility, and risk of OA onset in obese subjects could be affected by common genetic factors<sup>127,128</sup>. Since 2007, the single nucleotide polymorphism in the fat mass and obesity-associated (FTO) gene has been associated with risk of excess fat mass and obesity in several populations, so investigating this gene in OA could be of interest<sup>129</sup>. A genome-wide study demonstrated that knee and hip OA were associated with the FTO polymorphism, but this association was mediated by BMI<sup>130,131</sup>. Interestingly, obesity, metabolic disorders and OA are associated with IL-6 or leptin polymorphisms, which could be involved in MetS-associated OA pathogenesis<sup>132–134</sup>.

### Chronic low-grade inflammation: consequence or cause of pathological aging?

A common hypothesis is that metabolic disturbances precede and induce systemic chronic inflammation, which causes joint deterioration. Another theory has raised the concept of “inflammaging” (for inflammation and aging), with inflammation as the direct consequence of aging. Aging is associated with cellular senescence, immunosenescence, debris accumulation and harmful products such as ROS and also microbiota change (i.e., endotoxin accumulation) leading to exacerbated and sustained pro-inflammatory processes<sup>135</sup>. All these factors are also involved in other age-related diseases (e.g., cancer, atherosclerosis, Alzheimer disease). Thus, inflammaging could be the common biological background of all these age-related diseases. However, the phenomenon is probably more complex because inflammation, whatever its cause, is also responsible for accelerated aging.

### The role of inflammation in OA pain: is MetS OA the most painful phenotype?

Pain during OA is a complex phenomenon involving subchondral bone, synovium and articular capsule because cartilage is not innervated. Furthermore, pain in the setting of MetS-associated OA is somewhat peculiar: BMI as well as MetS is associated with increased OA pain intensity in all localisations (knee, hip and hand)<sup>26,136</sup>. Moreover, mechanical load and increased IL-1 $\beta$  level as well as adipokine levels increase nerve growth factor released by chondrocytes, an important mediator of pain related to OA<sup>137</sup>. Because dietary intake could modify the inflammatory state, it may be also implicated in OA-related pain<sup>138</sup>. However, depression, frequent in the obese population, is also associated with increased serum IL-6 and tumor necrosis factor  $\alpha$  levels. These pro-inflammatory cytokines may decrease serotonin levels via tryptophan depletion and sustained hypothalamo-pituitary-adrenocortical stimulation, which leads to cortisol resistance in depression pathophysiology<sup>139</sup>. Finally, a complex vicious circle results because pain induces disability, which in turn promotes obesity (Fig. 2). All these data are therefore to be considered in the




Fig. 2. How chronic inflammation related to obesity and metabolic syndrome could lead to osteoarthritis pain; the vicious circle of pain.

**Table 1**  
Research agenda

Research agenda
<ul style="list-style-type: none"> <li>• Link between hypertension and osteoarthritis</li> <li>• Effect of antidiabetic drugs in OA</li> <li>• Effect of antihypertensive drugs in OA</li> <li>• Investigation of anti-adipokines therapies in OA</li> <li>• Investigation of PPAR gamma agonists in OA</li> <li>• Is OA an independent risk factor for metabolic and cardiovascular diseases?</li> <li>• AGEs in type 2 diabetes-related OA pathophysiology and “anti-AGE” therapies in OA</li> <li>• Insulin resistance of joint cells in type 2 diabetes and obesity</li> <li>• Gut microbiota in OA and especially in obese patients</li> <li>• Pain mediators and OA in the metabolic OA phenotype</li> </ul>

development of new therapeutic strategies of MetS-associated OA (Table 1).

## Conclusions

OA is now classified according to several phenotypes based on risk factors. Here, we describe the relevant mechanisms implicated in one of these phenotypes, MetS-associated OA, with chronic inflammation as the cornerstone. Through multiple pathogenic pathways (i.e., adipokines, AGEs, oxidative stress) related to fat mass and metabolic disturbances, systemic inflammation leads to joint degradation. The concept allows for better understanding how loss of weight or modification of dietary intake may be beneficial for the joint in addition to decreasing mechanical load. Beyond modifying the excess fat mass, better control of each metabolic disturbance should slow the onset and progression of OA and should be considered in the therapeutic objectives of MetS-associated OA. Despite no strong conclusions about statins because of contradictory results, pioneering studies for OA treatment have recently been published<sup>140–142</sup>. We can consider new therapeutic strategies targeted to specific mechanisms such as oxidative stress or AGE production<sup>143</sup>. Other OA phenotypes such as post-traumatic and aging OA need investigation, and because OA seems to affect the onset of other chronic diseases, the impact on metabolic disturbances needs to be investigated<sup>144</sup>. The description of this new MetS-associated OA phenotype should lead to designing clinical trials in this specific subset of OA patients.

## Contributions

All authors made substantial contributions to (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.

## Declaration of funding

AC, FB and JS are supported by Fondation Arthritis Jacques Courtin (ROAD network).

OG is Staff Personnel of Xunta de Galicia (SERGAS) through a research-staff stabilization contract (ISCIII/SERGAS). Oreste Gualillo is supported by Instituto de Salud Carlos III (PI11/01073 and PI14/00016). OG is a member of RETICS Programme, RD12/0009/0008 (RIER:Red de Investigación en Inflamación y Enfermedades Reumáticas) via Instituto de Salud Carlos III (ISCIII).

## Competing interest statement

The authors have no competing interest to declare.

## Conflict of interest statement

The authors have no conflict of interest for this work.

## Acknowledgments

The authors thank Laura Smales (BioMedEditing, Toronto, Canada) for editing the manuscript and Charlotte Clergier (Paris, France) for the design of the figures.

## References

1. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. *Nat Rev Rheumatol* 2010;6:625–35, <http://dx.doi.org/10.1038/nrrheum.2010.159>.
2. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheum* 2012;64:1697–707, <http://dx.doi.org/10.1002/art.34453>.
3. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J-P, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. *Nat Rev Rheumatol* 2011;7:33–42, <http://dx.doi.org/10.1038/nrrheum.2010.196>.
4. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. *Lancet* 2011;377:2115–26, [http://dx.doi.org/10.1016/S0140-6736\(11\)60243-2](http://dx.doi.org/10.1016/S0140-6736(11)60243-2).
5. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 2006;444:860–7, <http://dx.doi.org/10.1038/nature05485>.
6. Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. *Am J Epidemiol* 1988;128:179–89.
7. Lohmander LS, Gerhardsson de Verdier M, Roloff J, Nilsson PM, Engström G. Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study. *Ann Rheum Dis* 2009;68:490–6, <http://dx.doi.org/10.1136/ard.2008.089748>.
8. Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch G, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. *Ann Rheum Dis* 2010;69:761–5, <http://dx.doi.org/10.1136/ard.2008.106930>.
9. Mueller WH, Wear ML, Hanis CL, Emerson JB, Barton SA, Hewett-Emmett D, et al. Which measure of body fat distribution is best for epidemiologic research? *Am J Epidemiol* 1991;133:858–69.
10. Akpinar E, Bashan I, Bozdemir N, Saatci E. Which is the best anthropometric technique to identify obesity: body mass index, waist circumference or waist-hip ratio? *Coll Antropol* 2007;31:387–93.
11. Samsell L, Regier M, Walton C, Cottrell L. Importance of android/gynoid fat ratio in predicting metabolic and cardiovascular disease risk in normal weight as well as overweight and obese children. *J Obes* 2014;2014:846578, <http://dx.doi.org/10.1155/2014/846578>.
12. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. *Diabetes* 2003;52:172–9.
13. Zhu S, Heshka S, Wang Z, Shen W, Allison DB, Ross R, et al. Combination of BMI and waist circumference for identifying cardiovascular risk factors in whites. *Obes Res* 2004;12:633–45, <http://dx.doi.org/10.1038/oby.2004.73>.
14. Wildman RP, Gu D, Reynolds K, Duan X, Wu X, He J. Are waist circumference and body mass index independently

- associated with cardiovascular disease risk in Chinese adults? *Am J Clin Nutr* 2005;82:1195–202.
15. Visser AW, Ioan-Facsinay A, de Mutsert R, Widya RL, Loef M, de Roos A, et al. Adiposity and hand osteoarthritis: the Netherlands Epidemiology of Obesity study. *Arthritis Res Ther* 2014;16:R19, <http://dx.doi.org/10.1186/ar4447>.
  16. Wang Y, Simpson JA, Wluka AE, Teichtahl AJ, English DR, Giles GG, et al. Relationship between body adiposity measures and risk of primary knee and hip replacement for osteoarthritis: a prospective cohort study. *Arthritis Res Ther* 2009;11:R31, <http://dx.doi.org/10.1186/ar2636>.
  17. Hajat C, Shather Z. Prevalence of metabolic syndrome and prediction of diabetes using IDF versus ATPIII criteria in a Middle East population. *Diabetes Res Clin Pract* 2012;98:481–6, <http://dx.doi.org/10.1016/j.diabres.2012.09.037>.
  18. Hari P, Nerusu K, Veeranna V, Sudhakar R, Zalawadiya S, Ramesh K, et al. A gender-stratified comparative analysis of various definitions of metabolic syndrome and cardiovascular risk in a multiethnic U.S. population. *Metab Syndr Relat Disord* 2012;10:47–55, <http://dx.doi.org/10.1089/met.2011.0087>.
  19. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Arterioscler Thromb Vasc Biol* 2004;24:e149–61, <http://dx.doi.org/10.1161/01.ATV.0000133317.49796.0E>.
  20. Alberti KGMM, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. *Lancet* 2005;366:1059–62, [http://dx.doi.org/10.1016/S0140-6736\(05\)67402-8](http://dx.doi.org/10.1016/S0140-6736(05)67402-8).
  21. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640–5, <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644>.
  22. Yoshimura N, Muraki S, Oka H, Tanaka S, Kawaguchi H, Nakamura K, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. *Osteoarthritis Cartilage* 2012;20:1217–26, <http://dx.doi.org/10.1016/j.joca.2012.06.006>.
  23. Sowers M, Karvonen-Gutierrez CA, Palmieri-Smith R, Jacobson JA, Jiang Y, Ashton-Miller JA. Knee osteoarthritis in obese women with cardiometabolic clustering. *Arthritis Rheum* 2009;61:1328–36, <http://dx.doi.org/10.1002/art.24739>.
  24. Monira Hussain S, Wang Y, Cicuttini FM, Simpson JA, Giles GG, Graves S, et al. Incidence of total knee and hip replacement for osteoarthritis in relation to the metabolic syndrome and its components: a prospective cohort study. *Semin Arthritis Rheum* 2014;43:429–36, <http://dx.doi.org/10.1016/j.semarthrit.2013.07.013>.
  25. Dahaghin S, Bierma-Zeinstra SMA, Koes BW, Hazes JMW, Pols H a P. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. *Ann Rheum Dis* 2007;66:916–20, <http://dx.doi.org/10.1136/ard.2005.045724>.
  26. Shin D. Association between metabolic syndrome, radiographic knee osteoarthritis, and intensity of knee pain: results of a national survey. *J Clin Endocrinol Metab* 2014;99:3177–83, <http://dx.doi.org/10.1210/jc.2014-1043>.
  27. Visser AW, de Mutsert R, le Cessie S, den Heijer M, Rosendaal FR, Kloppenburg M, for the NEO Study Group. The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. *Ann Rheum Dis* 2014, <http://dx.doi.org/10.1136/annrheumdis-2013-205012>.
  28. Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. *Postgrad Med* 2009;121:9–20, <http://dx.doi.org/10.3810/pgm.2009.11.2073>.
  29. Berenbaum F. Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. *Ann Rheum Dis* 2011;70:1354–6, <http://dx.doi.org/10.1136/ard.2010.146399>.
  30. Schett G, Kleyer A, Perricone C, Sahinbegovic E, Iagnocco A, Zwerina J, et al. Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. *Diabetes Care* 2013;36:403–9, <http://dx.doi.org/10.2337/dc12-0924>.
  31. Magnusson K, Hagen KB, Osterås N, Nordsletten L, Natvig B, Haugen IK. Diabetes is associated with increased hand pain in erosive hand osteoarthritis – data from a population-based study. *Arthritis Care Res (Hoboken)* 2014, <http://dx.doi.org/10.1002/acr.22460>.
  32. Nieves-Plaza M, Castro-Santana LE, Font YM, Mayor AM, Vilá LM. Association of hand or knee osteoarthritis with diabetes mellitus in a population of Hispanics from Puerto Rico. *J Clin Rheumatol* 2013;19:1–6, <http://dx.doi.org/10.1097/RHU.0b013e31827cd578>.
  33. Louati K, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: a systematic literature review and meta-analysis. *Ann Rheum Dis* 2014;7(Suppl 2).
  34. Addimanda O, Mancarella L, Dolzani P, Ramonda R, Fioravanti A, Brusi V, et al. Clinical associations in patients with hand osteoarthritis. *Scand J Rheumatol* 2012;41:310–3, <http://dx.doi.org/10.3109/03009742.2012.656699>.
  35. Stürmer T, Sun Y, Sauerland S, Zeissig I, Günther KP, Puhl W, et al. Serum cholesterol and osteoarthritis. The baseline examination of the Ulm Osteoarthritis Study. *J Rheumatol* 1998;25:1827–32.
  36. Hoeven TA, Kavousi M, Clockaerts S, Kerkhof HJ, van Meurs JB, Franco O, et al. Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam Study. *Ann Rheum Dis* 2013;72:646–51, <http://dx.doi.org/10.1136/annrheumdis-2011-201178>.
  37. Jonsson H, Helgadóttir GP, Aspelund T, Eiriksdóttir G, Sigurdsson S, Ingvarsson T, et al. Hand osteoarthritis in older women is associated with carotid and coronary atherosclerosis: the AGES Reykjavik study. *Ann Rheum Dis* 2009;68:1696–700, <http://dx.doi.org/10.1136/ard.2008.096289>.
  38. Koutroumpas A, Giannoukas A, Zintzaras E, Exarchou E, Baliakos A, Makaritsis K, et al. Erosive hand osteoarthritis is associated with Subclinical atherosclerosis and endothelial dysfunction. *Int J Biomed Sci* 2013;9:217–23.
  39. Cemeroglu O, Aydın HI, Yasar ZS, Bozduman F, Saglam M, Selcoki Y, et al. Hand and heart, hand in hand: is radiological hand osteoarthritis associated with atherosclerosis? *Int J Rheum Dis* 2014;17:299–303, <http://dx.doi.org/10.1111/1756-185X.12251>.
  40. Jonsson H, Helgadóttir GP, Aspelund T, Eiriksdóttir G, Sigurdsson S, Siggeirsdóttir K, et al. The presence of total knee or hip replacements due to osteoarthritis enhances the positive association between hand osteoarthritis and atherosclerosis in women: the AGES-Reykjavik study. *Ann Rheum Dis* 2011;70:1087–90, <http://dx.doi.org/10.1136/ard.2010.144980>.

41. Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. *BMJ* 2011;342:d1165.
42. Liu R, Kwok WY, Vliet Vlieland TP, Kroon HM, Meulenbelt I, Houwing-Duistermaat JJ, et al. Mortality in osteoarthritis patients. *Scand J Rheumatol* 2014;1–4, <http://dx.doi.org/10.3109/03009742.2014.922213>.
43. Hoeven TA, Leening MJ, Bindels PJ, Castaño-Betancourt M, van Meurs JB, Franco OH, et al. Disability and not osteoarthritis predicts cardiovascular disease: a prospective population-based cohort study. *Ann Rheum Dis* 2014, <http://dx.doi.org/10.1136/annrheumdis-2013-204388>.
44. Haugen IK, Ramachandran VS, Misra D, Neogi T, Niu J, Yang T, et al. Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham heart study. *Ann Rheum Dis* 2015;74:74–81, <http://dx.doi.org/10.1136/annrheumdis-2013-203789>.
45. Wang Y, Novera D, Wluka AE, Fairley J, Giles GG, O'Sullivan R, et al. Association between popliteal artery wall thickness and knee structure in adults without clinical disease of the knee: a prospective cohort study. *Arthritis Rheum (Hoboken, NJ)* 2015;67:414–22, <http://dx.doi.org/10.1002/art.38922>.
46. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005;115:1111–9, <http://dx.doi.org/10.1172/JCI25102>.
47. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994;372:425–32, <http://dx.doi.org/10.1038/372425a0>.
48. Scotece M, Conde J, Vuolteenaho K, Koskinen A, López V, Gómez-Reino J, et al. Adipokines as drug targets in joint and bone disease. *Drug Discov Today* 2014;19:241–58, <http://dx.doi.org/10.1016/j.drudis.2013.07.012>.
49. Scotece M, Conde J, Gómez R, López V, Pino J, González A, et al. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. *Mediators Inflamm* 2012;2012:125458, <http://dx.doi.org/10.1155/2012/125458>.
50. Conde J, Scotece M, López V, Gómez R, Lago F, Pino J, et al. Adipokines: novel players in rheumatic diseases. *Discov Med* 2013;15:73–83.
51. Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases? *Nat Rev Rheumatol* 2011;7:528–36, <http://dx.doi.org/10.1038/nrrheum.2011.107>.
52. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. *Nat Clin Pract Rheumatol* 2007;3:716–24, <http://dx.doi.org/10.1038/ncprheum0674>.
53. Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, Netter P, et al. Evidence for a key role of leptin in osteoarthritis. *Arthritis Rheum* 2003;48:3118–29, <http://dx.doi.org/10.1002/art.11303>.
54. Simopoulou T, Malizos KN, Iliopoulos D, Stefanou N, Papatheodorou L, Ioannou M, et al. Differential expression of leptin and leptin's receptor isoform (Ob-Rb) mRNA between advanced and minimally affected osteoarthritic cartilage; effect on cartilage metabolism. *Osteoarthritis Cartilage* 2007;15:872–83, <http://dx.doi.org/10.1016/j.joca.2007.01.018>.
55. Tong KM, Shieh DC, Chen CP, Tzeng CY, Wang SP, Huang KC, et al. Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. *Cell Signal* 2008;20:1478–88, <http://dx.doi.org/10.1016/j.cellsig.2008.04.003>.
56. Yang WH, Liu SC, Tsai CH, Fong YC, Wang SJ, Chang YS, et al. Leptin induces IL-6 expression through OBRI receptor signaling pathway in human synovial fibroblasts. *PLoS ONE* 2013;8:e75551, <http://dx.doi.org/10.1371/journal.pone.0075551>.
57. Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Päiväranta U, Moilanen T, et al. Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage—mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. *Mediat Inflamm* 2009;2009:345838, <http://dx.doi.org/10.1155/2009/345838>.
58. Iliopoulos D, Malizos KN, Tsezou A. Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. *Ann Rheum Dis* 2007;66:1616–21, <http://dx.doi.org/10.1136/ard.2007.069377>.
59. Laiguillon MC, Houard X, Bougault C, Gosset M, Nourissat G, Sautet A, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. *Arthritis Res Ther* 2014;16:R38, <http://dx.doi.org/10.1186/ar4467>.
60. Yammani RR, Loeser RF. Extracellular nicotinamide phosphoribosyltransferase (NAMPT/visfatin) inhibits insulin-like growth factor-1 signaling and proteoglycan synthesis in human articular chondrocytes. *Arthritis Res Ther* 2012;14:R23, <http://dx.doi.org/10.1186/ar3705>.
61. Hong EH, Yun HS, Kim J, Um HD, Lee KH, Kang CM, et al. Nicotinamide phosphoribosyltransferase is essential for interleukin-1beta-mediated dedifferentiation of articular chondrocytes via SIRT1 and extracellular signal-regulated kinase (ERK) complex signaling. *J Biol Chem* 2011;286:28619–31, <http://dx.doi.org/10.1074/jbc.M111.219832>.
62. Gabay O, Zaal KJ, Sanchez C, Dvir-Ginzberg M, Gagarina V, Song Y, et al. Sirt1-deficient mice exhibit an altered cartilage phenotype. *Joint Bone Spine* 2013;80:613–20, <http://dx.doi.org/10.1016/j.jbspin.2013.01.001>.
63. Dvir-Ginzberg M, Steinmeyer J. Towards elucidating the role of SirT1 in osteoarthritis. *Front Biosci (Landmark Ed)* 2013;18:343–55.
64. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. *Osteoarthritis Cartilage* 2008;16:1101–9, <http://dx.doi.org/10.1016/j.joca.2007.12.008>.
65. Koskinen A, Juslin S, Nieminen R, Moilanen T, Vuolteenaho K, Moilanen E. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. *Arthritis Res Ther* 2011;13:R184, <http://dx.doi.org/10.1186/ar3512>.
66. Yang S, Ryu JH, Oh H, Jeon J, Kwak JS, Kim JH, et al. NAMPT (visfatin), a direct target of hypoxia-inducible factor-2 $\alpha$ , is an essential catabolic regulator of osteoarthritis. *Ann Rheum Dis* 2013, <http://dx.doi.org/10.1136/annrheumdis-2013-204355>.
67. Katz JD, Agrawal S, Velasquez M. Getting to the heart of the matter: osteoarthritis takes its place as part of the metabolic syndrome. *Curr Opin Rheumatol* 2010;22:512–9, <http://dx.doi.org/10.1097/BOR.0b013e32833bfb4b>.
68. Berenbaum F, Eymard F, Houard X. Osteoarthritis, inflammation and obesity. *Curr Opin Rheumatol* 2013;25:114–8, <http://dx.doi.org/10.1097/BOR.0b013e32835a9414>.



69. Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. *Nat Rev Rheumatol* 2012;8:729–37, <http://dx.doi.org/10.1038/nrrheum.2012.135>.
70. Henrotin YE, Bruckner P, Pujol J-PL. The role of reactive oxygen species in homeostasis and degradation of cartilage. *Osteoarthritis Cartilage* 2003;11:747–55.
71. Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. *Gene* 2013;527:440–7, <http://dx.doi.org/10.1016/j.gene.2013.05.069>.
72. Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. *Nat Rev Rheumatol* 2011;7:161–9, <http://dx.doi.org/10.1038/nrrheum.2010.213>.
73. Marcu KB, Otero M, Olivetto E, Borzi RM, Goldring MB. NF-kappaB signaling: multiple angles to target OA. *Curr Drug Targets* 2010;11:599–613.
74. Ramakrishnan P, Brouillette M, Martin J. Oxidative conditioning and treatment for osteoarthritis. In: *Studies on Arthritis and Joint Disorders*. Humana Press/Springer; 2013.
75. Rosa SC, Gonçalves J, Judas F, Mobasher A, Lopes C, Mendes AF. Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage. *Arthritis Res Ther* 2009;11:R80, <http://dx.doi.org/10.1186/ar2713>.
76. Conde J, Gomez R, Bianco G, Scotecce M, Lear P, Dieguez C, et al. Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. *Ann Rheum Dis* 2011;70:551–9, <http://dx.doi.org/10.1136/ard.2010.132399>.
77. Lippiello L, Walsh T, Fienhold M. The association of lipid abnormalities with tissue pathology in human osteoarthritic articular cartilage. *Metab Clin Exp* 1991;40:571–6.
78. Alvarez-Garcia O, Rogers NH, Smith RG, Lotz MK. Palmitate has proapoptotic and proinflammatory effects on articular cartilage and synergizes with interleukin-1. *Arthritis Rheum (Hoboken, NJ)* 2014;66:1779–88, <http://dx.doi.org/10.1002/art.38399>.
79. Mooney RA, Sampson ER, Lerea J, Rosier RN, Zuscik MJ. High-fat diet accelerates progression of osteoarthritis after meniscal/ligamentous injury. *Arthritis Res Ther* 2011;13:R198, <http://dx.doi.org/10.1186/ar3529>.
80. Knott L, Avery NC, Hollander AP, Tarlton JF. Regulation of osteoarthritis by omega-3 (n-3) polyunsaturated fatty acids in a naturally occurring model of disease. *Osteoarthritis Cartilage* 2011;19:1150–7, <http://dx.doi.org/10.1016/j.joca.2011.06.005>.
81. Wu CL, Jain D, McNeill JN, Little D, Anderson JA, Huebner JL, et al. Dietary fatty acid content regulates wound repair and the pathogenesis of osteoarthritis following joint injury. *Ann Rheum Dis* 2014, <http://dx.doi.org/10.1136/annrheumdis-2014-205601>.
82. Simopoulos AP. Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. *World Rev Nutr Diet* 2011;102:10–21, <http://dx.doi.org/10.1159/000327785>.
83. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. *J Am Coll Nutr* 2002;21:495–505.
84. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J Biol Chem* 1995;270:12953–6.
85. Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N, et al. Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. *Arthritis Res Ther* 2007;9:R31, <http://dx.doi.org/10.1186/ar2151>.
86. Fahmi H, Pelletier J-P, Mineau F, Martel-Pelletier J. 15d-PGJ(2) is acting as a “dual agent” on the regulation of COX-2 expression in human osteoarthritic chondrocytes. *Osteoarthritis Cartilage* 2002;10:845–8.
87. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. *Arthritis Rheum* 2001;44:595–607, [http://dx.doi.org/10.1002/1529-0131\(200103\)44.3<595::AID-ANR108>3.0.CO;2-8](http://dx.doi.org/10.1002/1529-0131(200103)44.3<595::AID-ANR108>3.0.CO;2-8).
88. Ji JD, Cheon H, Jun JB, Choi SJ, Kim YR, Lee YH, et al. Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. *J Autoimmun* 2001;17:215–21, <http://dx.doi.org/10.1006/jaut.2001.0542>.
89. Vasheghani F, Zhang Y, Li YH, Blati M, Fahmi H, Lussier B, et al. PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. *Ann Rheum Dis* 2015;74:569–78, <http://dx.doi.org/10.1136/annrheumdis-2014-205743>.
90. Stienstra R, Haim Y, Riahi Y, Netea M, Rudich A, Leibowitz G. Autophagy in adipose tissue and the beta cell: implications for obesity and diabetes. *Diabetologia* 2014;57:1505–16, <http://dx.doi.org/10.1007/s00125-014-3255-3>.
91. Nagai R, Horiuchi S, Unno Y. Application of monoclonal antibody libraries for the measurement of glycation adducts. *Biochem Soc Trans* 2003;31:1438–40, <http://dx.doi.org/10.1042/>.
92. Day JF, Ingebretsen CG, Ingebretsen WR, Baynes JW, Thorpe SR. Nonenzymatic glycosylation of serum proteins and hemoglobin: response to changes in blood glucose levels in diabetic rats. *Diabetes* 1980;29:524–7.
93. Hirata K, Kubo K. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. *Endocr J* 2004;51:537–44.
94. Gaens KHJ, Stehouwer CDA, Schalkwijk CG. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. *Curr Opin Lipidol* 2013;24:4–11, <http://dx.doi.org/10.1097/MOL.0b013e32835aea13>.
95. Gaens KH, Goossens GH, Niessen PM, van Greevenbroek MM, van der Kallen CJ, Niessen HW, et al. Nε-(carboxymethyl) lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. *Arterioscler Thromb Vasc Biol* 2014;34:1199–208, <http://dx.doi.org/10.1161/ATVBAHA.113.302281>.
96. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. *Arthritis Rheum* 2002;46:114–23, [http://dx.doi.org/10.1002/1529-0131\(200201\)46.1<114::AID-ART10025>3.0.CO;2-P](http://dx.doi.org/10.1002/1529-0131(200201)46.1<114::AID-ART10025>3.0.CO;2-P).
97. Vashishta D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. *Bone* 2001;28:195–201.
98. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced

- glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. *Diabetologia* 1997;40:764–9.
99. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. *J Am Soc Nephrol* 2000;11:1656–66.
  100. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. *Am J Pathol* 1993;143:1649–56.
  101. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. *Diabetologia* 2004;47:1324–30, <http://dx.doi.org/10.1007/s00125-004-1451-2>.
  102. Oren TW, Botolin S, Williams A, Bucknell A, King KB. Arthroplasty in veterans: analysis of cartilage, bone, serum, and synovial fluid reveals differences and similarities in osteoarthritis with and without comorbid diabetes. *J Rehabil Res Dev* 2011;48:1195–210.
  103. Rasheed Z, Haqqi TM. Endoplasmic reticulum stress induces the expression of COX-2 through activation of eIF2 $\alpha$ , p38-MAPK and NF- $\kappa$ B in advanced glycation end products stimulated human chondrocytes. *Biochim Biophys Acta* 2012;1823:2179–89, <http://dx.doi.org/10.1016/j.bbamcr.2012.08.021>.
  104. Rasheed Z, Akhtar N, Haqqi TM. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear factor- $\kappa$ B in human osteoarthritis chondrocytes. *Rheumatology (Oxford)* 2011;50:838–51, <http://dx.doi.org/10.1093/rheumatology/keq380>.
  105. Nah SS, Choi IY, Lee CK, Oh JS, Kim YG, Moon HB, et al. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. *Rheumatology (Oxford)* 2008;47:425–31, <http://dx.doi.org/10.1093/rheumatology/kem376>.
  106. Franke S, Sommer M, Ruster C, Bondeva T, Marticke J, Hofmann G, et al. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. *Arthritis Res Ther* 2009;11:R136, <http://dx.doi.org/10.1186/ar2807>.
  107. Chen YJ, Sheu ML, Tsai KS, Yang RS, Liu SH. Advanced glycation end products induce peroxisome proliferator-activated receptor  $\gamma$  down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. *PLoS ONE* 2013;8:e66611, <http://dx.doi.org/10.1371/journal.pone.0066611>.
  108. Nah S-S, Choi I-Y, Yoo B, Kim YG, Moon H-B, Lee C-K. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. *FEBS Lett* 2007;581:1928–32, <http://dx.doi.org/10.1016/j.febslet.2007.03.090>.
  109. Yamabe S, Hirose J, Uehara Y, Okada T, Okamoto N, Oka K, et al. Intracellular accumulation of advanced glycation end products induces apoptosis via endoplasmic reticulum stress in chondrocytes. *FEBS J* 2013;280:1617–29, <http://dx.doi.org/10.1111/febs.12170>.
  110. Verzijl N, DeGroot J, Oldehinkel E, Bank RA, Thorpe SR, Baynes JW, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. *Biochem J* 2000;350:381–7.
  111. Atayde SA, Yoshinari NH, Nascimento DP, Catanozi S, Andrade PC, Velosa AP, et al. Experimental diabetes modulates collagen remodelling of joints in rats. *Histol Histopathol* 2012;27:1471–9.
  112. Mobasheri A, Neama G, Bell S, Richardson S, Carter SD. Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. *Cell Biol Int* 2002;26:297–300, <http://dx.doi.org/10.1006/cbir.2001.0850>.
  113. Shikhman AR, Brinson DC, Valbracht J, Lotz MK. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. *J Immunol* 2001;167:7001–8.
  114. Yang H, Jin X, Kei Lam CW, Yan S-K. Oxidative stress and diabetes mellitus. *Clin Chem Lab Med* 2011;2011(49):1773–82, <http://dx.doi.org/10.1515/CCLM.250>.
  115. Silveri F, Brecciaroli D, Argentati F, Cervini C. Serum levels of insulin in overweight patients with osteoarthritis of the knee. *J Rheumatol* 1994;21:1899–902.
  116. Ansboro S, Maynard R, Hamada D, Farnsworth C, Mooney R, Zuscik MJ. Synovial insulin resistance is linked to osteoarthritis in type 2 diabetes. In: *ASBMR Congress: Poster 1010 2014*.
  117. Rosa SC, Rufino AT, Judas F, Tenreiro C, Lopes MC, Mendes AF. Expression and function of the insulin receptor in normal and osteoarthritic human chondrocytes: modulation of anabolic gene expression, glucose transport and GLUT-1 content by insulin. *Osteoarthritis Cartilage* 2011;19:719–27, <http://dx.doi.org/10.1016/j.joca.2011.02.004>.
  118. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? *Ann Rheum Dis* 2005;64:1539–41, <http://dx.doi.org/10.1136/ard.2005.039263>.
  119. Findlay DM. Vascular pathology and osteoarthritis. *Rheumatology (Oxford)* 2007;46:1763–8, <http://dx.doi.org/10.1093/rheumatology/kem191>.
  120. Amir G, Goldfarb AW, Nyska M, Redlich M, Nyska A, Nitzan DW. 2-Butoxyethanol model of haemolysis and disseminated thrombosis in female rats: a preliminary study of the vascular mechanism of osteoarthritis in the temporomandibular joint. *Br J Oral Maxillofac Surg* 2011;49:21–5, <http://dx.doi.org/10.1016/j.bjoms.2009.11.011>.
  121. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. *Rheumatology (Oxford)* 2005;44:7–16, <http://dx.doi.org/10.1093/rheumatology/keh344>.
  122. Metcalfe D, Harte AL, Aletrari MO, Al Daghri NM, Al Disi D, Tripathi G, et al. Does endotoxaemia contribute to osteoarthritis in obese patients? *Clin Sci* 2012;123:627–34, <http://dx.doi.org/10.1042/CS20120073>.
  123. Creely SJ, McTernan PG, Kusmins CM, Fisher fM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. *Am J Physiol Endocrinol Metab* 2007;292:E740–7, <http://dx.doi.org/10.1152/ajpendo.00302.2006>.
  124. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. *Nature* 2013;500:585–8, <http://dx.doi.org/10.1038/nature12480>.
  125. Daniel H, Moghaddas Gholami A, Berry D, Desmarchelier C, Hahne H, Loh G, et al. High-fat diet alters gut microbiota physiology in mice. *ISME J* 2014;8:295–308, <http://dx.doi.org/10.1038/ismej.2013.155>.
  126. Bobacz K, Sunk IG, Hofstaetter JG, Amoyo L, Toma CD, Akira S, et al. Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. *Arthritis Rheum* 2007;56:1880–93, <http://dx.doi.org/10.1002/art.22637>.

127. Zhu J, Zong G, Lu L, Gan W, Ji L, Hu R, et al. Association of genetic predisposition to obesity with type 2 diabetes risk in Han Chinese individuals. *Diabetologia* 2014;57:1830–3, <http://dx.doi.org/10.1007/s00125-014-3308-7>.
128. Qian Y, Liu S, Lu F, Li H, Dong M, Lin Y, et al. Genetic variant in fat mass and obesity-associated gene associated with type 2 diabetes risk in Han Chinese. *BMC Genet* 2013;14:86, <http://dx.doi.org/10.1186/1471-2156-14-86>.
129. Fawcett KA, Barroso I. The genetics of obesity: FTO leads the way. *Trends Genet* 2010;26:266–74, <http://dx.doi.org/10.1016/j.tig.2010.02.006>.
130. arcOGEN Consortium; arcOGEN Collaborators, Zeggini E, Panoutsopoulou K, Southam L, Rayner NW, Day-Williams AG, Lopes MC, et al. Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. *Lancet* 2012;380:815–23, [http://dx.doi.org/10.1016/S0140-6736\(12\)60681-3](http://dx.doi.org/10.1016/S0140-6736(12)60681-3).
131. Panoutsopoulou K, Metrustry S, Doherty SA, Laslett LL, Maciewicz RA, Hart DJ, et al. The effect of FTO variation on increased osteoarthritis risk is mediated through body mass index: a mendelian randomisation study. *Ann Rheum Dis* 2014;73:2082–6, <http://dx.doi.org/10.1136/annrheumdis-2013-203772>.
132. Goyenechea E, Parra D, Martínez JA. Impact of interleukin 6 – 174G>C polymorphism on obesity-related metabolic disorders in people with excess in body weight. *Metab Clin Exp* 2007;56:1643–8, <http://dx.doi.org/10.1016/j.metabol.2007.07.005>.
133. Honsawek S, Deepaisarnsakul B, Tanavalee A, Yuktanandana P, Bumrungrpanichthaworn P, Malila S, et al. Association of the IL-6 -174G/C gene polymorphism with knee osteoarthritis in a Thai population. *Genet Mol Res* 2011;10:1674–80.
134. Qin J, Shi D, Dai J, Zhu L, Tsezou A, Jiang Q. Association of the leptin gene with knee osteoarthritis susceptibility in a Han Chinese population: a case-control study. *J Hum Genet* 2010;55:704–6, <http://dx.doi.org/10.1038/jhg.2010.86>.
135. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci* 2014;69(Suppl 1):S4–9, <http://dx.doi.org/10.1093/gerona/glu057>.
136. Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A, Sarzi-Puttini P. Body mass and osteoarthritic pain: results from a study in general practice. *Clin Exp Rheumatol* 2013;31:843–9.
137. Pecchi E, Priam S, Gosset M, Pigenet A, Sudre L, Laiguillon MC, et al. Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. *Arthritis Res Ther* 2014;16:R16, <http://dx.doi.org/10.1186/ar4443>.
138. Griffin TM, Fermor B, Huebner JL, Kraus VB, Rodriguiz RM, Wetsel WC, et al. Diet-induced obesity differentially regulates behavioral, biomechanical, and molecular risk factors for osteoarthritis in mice. *Arthritis Res Ther* 2010;12:R130, <http://dx.doi.org/10.1186/ar3068>.
139. Postal M, Appenzeller S. The importance of cytokines and autoantibodies in depression. *Autoimmun Rev* 2014, <http://dx.doi.org/10.1016/j.autrev.2014.09.001>.
140. Riddle DL, Moxley G, Dumenci L. Associations between statin use and changes in pain, function and structural progression: a longitudinal study of persons with knee osteoarthritis. *Ann Rheum Dis* 2013;72:196–203, <http://dx.doi.org/10.1136/annrheumdis-2012-202159>.
141. Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM, Verhaar JA, Van Glabbeek F, Van Meurs JB, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. *Ann Rheum Dis* 2012;71:642–7, <http://dx.doi.org/10.1136/annrheumdis-2011-200092>.
142. Kadam UT, Blagojevic M, Belcher J. Statin use and clinical osteoarthritis in the general population: a longitudinal study. *J Gen Intern Med* 2013;28:943–9, <http://dx.doi.org/10.1007/s11606-013-2382-8>.
143. Canter PH, Wider B, Ernst E. The antioxidant vitamins A, C, E and selenium in the treatment of arthritis: a systematic review of randomized clinical trials. *Rheumatology (Oxford)* 2007;46:1223–33, <http://dx.doi.org/10.1093/rheumatology/kem116>.
144. Kyrkanides S, Tallents RH, Miller JN, Olschowka ME, Johnson R, Yang M, et al. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. *J Neuroinflammation* 2011;8:112, <http://dx.doi.org/10.1186/1742-2094-8-112>.